tiprankstipranks
Trending News
More News >

Nihon Chouzai Reports Extraordinary Losses and Earnings Shortfall for FY 2025

Story Highlights
  • Nihon Chouzai faced extraordinary losses due to impairment in its pharmacy business.
  • The company reported earnings shortfall due to lower prescription volumes and manufacturing issues.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Nihon Chouzai Reports Extraordinary Losses and Earnings Shortfall for FY 2025

Confident Investing Starts Here:

Nihon Chouzai Co ( (JP:3341) ) has shared an update.

Nihon Chouzai Co., Ltd. announced significant extraordinary losses for the fiscal year ending March 31, 2025, due to impairment losses in its Dispensing Pharmacy Business, totaling 4,132 million yen. The company also reported a shortfall in its consolidated earnings compared to its forecast, attributed to lower prescription volumes and manufacturing issues at its Kawauchi Plant, impacting sales and profitability.

More about Nihon Chouzai Co

Nihon Chouzai Co., Ltd. operates in the healthcare sector, primarily focusing on the Dispensing Pharmacy Business and the Pharmaceutical Manufacturing and Sales Business. The company is involved in the production and sale of generic drugs through its group company, Choseido Pharmaceutical.

YTD Price Performance: 0.25%

Technical Sentiment Signal: Strong Sell

Current Market Cap: $602.7M

See more data about 3341 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App